Abbott: Dyslipidemias trials

The registry lists 23 Dyslipidemias studies with Abbott as lead sponsor. 0 are open to participants now and 12 have results posted.

Phase 2 3Phase 3 18Phase 4 2No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A 12-week Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate/Simvastatin 145/20mg and Fenofibrate/Simvastatin 145/40mg Tablets Versus Fenofibrate or Simvastatin Monotherapies in Subjects With Abnormal Blood Levels of Fats (Lipids) and at High Risk of Cardiovascular DiseaseCompletedNCT01674712Phase 3Results posted
• A Study to Evaluate Fenofibrate Combination With Statin in Chinese Patients With DyslipidemicCompletedNCT01462877Phase 4Results posted
• Effect of Fenofibrate on Sleep Apnea SyndromeTerminatedNCT00816829Phase 2Results posted
• Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the BloodCompletedNCT00639158Phase 3Results posted
• Evaluation of a Flushing ASsessment Tool (FAST) in Subjects Receiving Niacin Extended-release Plus AspirinCompletedNCT00630877Phase 3Results posted
• Study to Evaluate the EFFECTS of Acetylsalicylic Acid (ASA) on Niaspan®-Induced Flushing in Subjects With DyslipidemiaCompletedNCT00626392Phase 3Results posted
• A Year 2, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed DyslipidemiaCompletedNCT00491530Phase 3Results posted
• An Open-Label Study to Compare the Lipid Effects of Niacin ER and Simvastatin (NS) to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia (SUPREME)CompletedNCT00465088Phase 3Results posted
• Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the BloodCompletedNCT00300482Phase 3Results posted
• Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the BloodCompletedNCT00300469Phase 3Results posted
• Evaluate Safety and Efficacy of ABT-335 in Combination With Simvastatin in Subjects With Multiple Abnormal Lipid Levels in the BloodCompletedNCT00300456Phase 3Results posted
• Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.CompletedNCT00300430Phase 3Results posted
• A Clinical Study to Evaluate the Effect of Mobile Applications "My A:Care" and "Smart Coach" on the Lipid-lowering Treatment Adherence of Subjects With Dyslipidemia in ThailandCompletedNCT05370703
• Post Marketing Surveillance of Safety and Efficacy for Cholib in Korean Patients Under the "New Drug Re-examination".CompletedNCT02489331
• Acceptability Study of a New Fixed Combination of Fenofibrate 80 mg BID and Metformin 1000 mg BID in Type 2 Diabetes and DyslipidemiaCompletedNCT00490178Phase 3
• Fenofibrate and Metformin Insulin Sensitivity in Type 2 Diabetics StudyTerminatedNCT00362765Phase 2/3
• Fenofibrate and Metformin Fixed Combination vs Metformin - FAME METFOCompletedNCT00362323Phase 3
• Fenofibrate and Metformin Fixed Combination vs Rosiglitazone - FAME ROSITerminatedNCT00361868Phase 3
• Fenofibrate in Dyslipidemia and Metformin-Controlled DiabetesCompletedNCT00349128Phase 2/3
• Acceptability of a Fixed Combination of Fenofibrate and MetforminCompletedNCT00348725Phase 3
• Safety & Efficacy of a Combination Niacin ER/Simvastatin in Patients With Dyslipidemia: A Dose-Ranging Study - SEACOASTCompletedNCT00082251Phase 3
• Evaluation of the Safety & Efficacy of a Combination of Niacin ER & Simvastatin in Patients With Dyslipidemia (OCEANS)CompletedNCT00080275Phase 3
• Comparative Efficacy Evaluation of Lipids When Treated With Niaspan & Statin or Other Lipid-Modifying Therapies-COMPELLCompletedNCT00079638Phase 4